Overview
A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2021-12-01
2021-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Bio-Thera Solutions
Criteria
Inclusion Criteria:- Compliance with the NMOSD diagnostic criteria developed by the 2015 International NMO
Diagnostic Team (IPND);
- 18-65 years old , male or female;
- At least 2 relapses occurred within 2 years before screening, or at least 1 relapse
within 1 year before screening;
- Discontinue the immunosuppressive agents such as azathioprine within 28 days before
the baseline;
- EDSS score ≤ 6;
- Men and women with fertility must agree to use effective methods of contraception
during treatment and within 12 months of treatment completion;
- Agree to participate in the trial and sign the informed consent in writing.
Exclusion Criteria:
- Any monoclonal antibody treatment was used within 6 months prior to dosing;
- Having been treated with anti-CD20 monoclonal antibody;
- Live vaccine received within 4 weeks before screening;
- Having participated in another clinical study within 1 month or 5 half-lives of the
drug prior to the baseline (whichever is longer);
- A history of allergies to monoclonal antibodies; severe allergic reaction to certain
foods or drugs;
- Abnormal liver function, kidney function and bone marrow reserve;
- HIV-positive history or HIV-positive at screening; hepatitis B and/or hepatitis C
history or hepatitis B surface antigen-positive at screening; or hepatitis C virus
(HCV) antibody positive; treponema pallidum antibody positive when enrolled;
- History of infections that investigators have identified as unsuitable for testing;
- Patients with a clear history of heart disease ;
- Have a history of mental disorders;
- Pregnant or lactating women, and female subjects who have a positive pregnancy test at
screening;
- None of the investigators or their relatives participating in the study could be
enrolled.